Global Migraine Drugs Market 2016-2020

  • ID: 3721900
  • Report
  • Region: Global
  • 63 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbott
  • Amgen
  • Dr. Reddy’s Laboratories
  • GlaxoSmithKline
  • Luitpold Pharmaceuticals
  • Pfizer
  • MORE
About Migraines

A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

The analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Allergan
- Endo International
- GlaxoSmithKline
- Impax
- Pfizer

Other prominent vendors
- Abbott
- Aegis Therapeutics
- Aeriel BioPharma
- Alder Biopharmaceuticals
- Amgen
- Astellas
- AstraZeneca
- Bayer
- CoLucid
- Dr. Reddy’s Laboratories
- Eisai
- Eli Lilly
- Ethypharm
- IntelGenx
- Johnson & Johnson
- Klaria
- Kowa Pharmaceuticals America
- Luitpold Pharmaceuticals
- Meda
- Merck
- OptiNose
- Pfizer
- Pozen
- Raptor
- RedHill
- SUDA
- Teva
- TG Therapeutics
- NValeant
- Winston Pharmaceuticals
- Zogenix

Market drivers
- Growing awareness about migraine and its treatment options
- For a full, detailed list, view the full report

Market challenges
- Lack of proper diagnosis
- For a full, detailed list, view the full report

Market trends
- Antimigraine devices and headbands
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Amgen
  • Dr. Reddy’s Laboratories
  • GlaxoSmithKline
  • Luitpold Pharmaceuticals
  • Pfizer
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Types
  • Cause
  • Management
  • Epidemiology
  • Economic burden
PART 06: Pipeline analysis
  • Semprana
  • Rizaport
  • Sumatriptan
  • DFN-11
  • Lasmiditan
  • SUD001
  • AMG 334
  • DFN-02
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by type of treatment
  • Preventative
  • Abortive
PART 09: Market segmentation by therapeutic class
  • Triptans
  • Ergot alkaloids
  • Other
PART 10: Geographical segmentation
  • Global migraine drugs market by geographical segmentation 2015-2020
  • Migraine drugs market in Americas
  • Migraine drugs market in EMEA
  • Migraine drugs market in APAC
PART 11: Market drivers
  • Growing awareness about migraine and its treatment options
  • Tentative approval of pipeline candidates
  • High unmet needs
  • Increased prevalence of migraines
PART 12: Impact of drivers

PART 13: Market challenges
  • Lack of proper diagnosis
  • Adverse effects of drugs
  • Increased preference for alternative therapies
  • Generic penetration
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Antimigraine devices and headbands
  • Increase in R&D
  • Novel product innovations
  • Strategic alliances
PART 16: Vendor landscape
  • Competitive scenario
  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer
  • Other prominent vendors
PART 17: Appendix
  • List of abbreviations
PART 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Percentage of migraine sufferers worldwide by gender
Exhibit 03: Global migraine drugs market: Pipeline portfolio
Exhibit 04: Global migraine drugs market 2015-2020 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Preventative medications based on efficacy of drugs
Exhibit 07: Medications used based on severity of migraines
Exhibit 08: Percentage share of preventative and abortive migraine medications in US 2015
Exhibit 09: Segmentation of global migraine drugs market by therapeutic class 2015
Exhibit 10: Market share of triptans by ROA 2015
Exhibit 11: Global migraine drugs market by geography 2015
Exhibit 12: Global migraine drugs market by geography 2015-2020 ($ millions)
Exhibit 13: Migraine drugs market in Americas 2015-2020 ($ billions)
Exhibit 14: Migraine drugs market in EMEA 2015-2020 ($ millions)
Exhibit 15: Migraine drugs market in APAC 2015-2020 ($ millions)
Exhibit 16: Impact of drivers
Exhibit 17: Percentage of population diagnosed with migraine in US 2014
Exhibit 18: Impact of drivers and challenges
Exhibit 19: Allergan: YoY growth rate and revenue of Botox 2012-2014 ($ millions)
Exhibit 20: Allergan: Key takeaways
Exhibit 21: Endo International: Key takeaways
Exhibit 22: GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 ($ millions)
Exhibit 23: GlaxoSmithKline: Key takeaways
Exhibit 24: Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 ($ millions)
Exhibit 25: Impax: Key takeaways
Exhibit 26: Pfizer: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
Exhibit 27: Pfizer: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Amgen
  • Dr. Reddy’s Laboratories
  • GlaxoSmithKline
  • Luitpold Pharmaceuticals
  • Pfizer
  • MORE
New Report Released: – Global Migraine Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Migraine Drugs Market: Allergan, Endo International, GlaxoSmithKline, Impax, and Pfizer.

Other Prominent Vendors in the market are: Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, and Zogenix.

Commenting on the report, an analyst from the research team said: “One market trend to watch for is the development and availability of antimigraine devices and headbands. Antimigraine drugs are associated with various side effects and show less tolerance among the patients. Thus, the need for new treatment options has led to the development of various devices in the market. Antimigraine devices and headbands are being increasingly preferred for the prevention of migraines. The FDA has approved Cerena Transcranial Magnetic Stimulator and the Cefaly Transcutaneous Electrical Nerve Stimulation device for migraine treatment. Cefaly is a plastic headband, which can be worn across the forehead.”

According to the report, a key market driver is the unmet needs of migraine sufferers around the world. Prophylactic therapy with improved efficacy and tolerability is one of the most significant unmet needs in individuals suffering from migraine. The US Agency for Healthcare Research and Quality estimated that only about 12% of the adults with migraines take preventive medications. The occurrence of side effects is the major reason that limits the use of migraine drugs. Moreover, there are still high levels of unmet need existing in certain niche populations, especially in patients who do not respond satisfactorily to triptans or patients for whom triptans are contraindicated.

Further, the report states that a challenge that could have a big impact on market growth is the lack of proper diagnosis of migraines.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Allergan
- Endo International
- GlaxoSmithKline
- Impax
- Pfizer
- Abbott
- Aegis Therapeutics
- Aeriel BioPharma
- Alder Biopharmaceuticals
- Amgen
- Astellas
- AstraZeneca
- Bayer
- CoLucid
- Dr. Reddy’s Laboratories
- Eisai
- Eli Lilly
- Ethypharm
- IntelGenx
- Johnson & Johnson
- Klaria
- Kowa Pharmaceuticals America
- Luitpold Pharmaceuticals
- Meda
- Merck
- OptiNose
- Pfizer
- Pozen
- Raptor
- RedHill
- SUDA
- Teva
- TG Therapeutics
- NValeant
- Winston Pharmaceuticals
- Zogenix.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll